U-BXRX

Q:BXRX - BAUDAX BIO INC - Website unknown - click to update

14:21:09 EDT

Sym-X	Bid - Ask					Last	Chg	%Ch	Vol	$Vol	#Tr	Open-Hi-Lo	Year Hi-Lo	Last Tr	News	Delay
BXRX - Q	not subscribed					0.0218							3.4699 0.0137	Feb 29	Oct 18	15 min RT 2¢

Trade times are ET. News times are ET. Bid/ask/vol sizes in thousands.
OTC Markets Indicators -- Primary Market: OTC Markets -- Tier: OTC Pink Current -- Status: Active

Fundamentals · Holders · Trade Workstation · Market Depth · 3 Month Closes · Technical Charts 1 yr | 2 yr | 3 yr | 5 yr | 10 yr | 15 yr | 20 yr · Live Charts 1 yr | 1 day · 1yr Bulletins · Historical · Portfolio

Recent Trades - All 0 today

More trades...

Time ET	Ex	Price	Change	Volume

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Date ET	Symbol	Type	Headline
2023-10-18 08:00	U:BXRX	News Release200	Baudax Bio Announces Corporate Update
2023-09-28 08:00	U:BXRX	News Release200	Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors
2023-09-07 08:00	U:BXRX	News Release200	Baudax Bio to Participate in the H.C. Wainwright Global Investment Conference
2023-08-23 08:00	U:BXRX	News Release200	Baudax Bio Announces Distribution of Series C Preferred Stock to Holders of its Common Stock
2023-08-17 08:00	U:BXRX	News Release200	Baudax Bio Announces $1.9 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
2023-08-16 08:00	U:BXRX	News Release200	Baudax Bio Reports Second Quarter 2023 Financial Results and Provides Business Update
2023-06-30 08:00	U:BXRX	News Release200	Baudax Bio Acquires TeraImmune, Inc.
2023-06-07 09:21	U:BXRX	News Release200	Baudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000
2023-06-06 09:00	U:BXRX	News Release200	Baudax Bio Announces Date of Reconvened Annual Meeting

Date ET

Symbol

Type

Headline

2023-10-18 08:00

U:BXRX

News Release

Baudax Bio Announces Corporate Update

2023-09-28 08:00

U:BXRX

News Release

Baudax Bio Announces Orphan Drug Designation Granted by U.S. FDA for TI-168 for the Treatment of Hemophilia A with Inhibitors